Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
24/7 Wall St. on MSN20h
Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street ExpertBillionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative ...
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...
While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...
Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...
Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...
Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai Inc. has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “n ...
Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback